Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

Autor: Ricardo Sant’Anna, Pablo Gallego, Lei Z. Robinson, Alda Pereira-Henriques, Nelson Ferreira, Francisca Pinheiro, Sebastian Esperante, Irantzu Pallares, Oscar Huertas, Maria Rosário Almeida, Natàlia Reixach, Raul Insa, Adrian Velazquez-Campoy, David Reverter, Núria Reig, Salvador Ventura

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)

Externí odkaz: https://doaj.org/article/e01ea5c5ac0a4bd48c5c5662836b01fd

A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease

Autor: Josep Gamez, Matilde Calopa, Esteban Muñoz, Aileen Ferré, Oscar Huertas, Kevin McAllister, Núria Reig, Catherine Scart‐Grès, Raúl Insa, Jaime Kulisevsky

Publikováno v: British journal of clinical pharmacologyREFERENCES.

The study's aim is to investigate the efficacy and safety of SOM3355 (bevantolol hydrochloride), a βA randomized, placebo-controlled proof-of-concept study was performed in 32 HD patients allocated to 2 arms of 4 sequential 6-week periods each. Pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4612ae6b2eca528af7cdc517d8b7bd3a
https://pubmed.ncbi.nlm.nih.gov/36494329

F40 Proof-of-concept study testing SOM3355, a VMAT2 inhibitor for the treatment of chorea in huntington’s disease

Autor: Oscar Huertas, Aileen Ferré, Kevin McAllister, Jaime Kulisevsky, Josep Gamez, Núria Reig, Raul Insa, Catherine Scart-Grès, Esteban Muñoz, Matilde Calopa

Publikováno v: F: Clinical studies: case reports, observational studies and trials.

Background SOM3355 (bevantolol hydrochloride), a β1-adrenoceptor blocker used in hypertension, was identified as a vesicular monoamine transporter type 2 (VMAT2) inhibitor by artificial intelligence screening, and then selected by in vitro functiona

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53e684082dde644a3457b6b244fbaf99
https://doi.org/10.1136/jnnp-2021-ehdn.83

560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections

Autor: Dong-Hae Shin, Núria Reig

Publikováno v: Open Forum Infectious Diseases

Background The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is seriously impacting health and economies all over the world. With more than 8 million diagnosed cases and close t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d671f3a742ce85ebb39e11f70eb2e33d
https://doi.org/10.1093/ofid/ofaa439.754

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

Autor: Natàlia Reixach, Salvador Ventura, Raul Insa, Ricardo Sant'Anna, Oscar Huertas, David Reverter, Adrián Velázquez-Campoy, Lei Z. Robinson, Sebastian Esperante, Nelson Ferreira, Maria Rosário Almeida, Pablo Gallego, Alda Pereira-Henriques, Irantzu Pallarès, Francisca Pinheiro, Núria Reig

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Nature Communications

13 pags, 6 figs, 1 tab. -- Supplementary information is available at the Publisher's web
Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggrega

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64234fcfaf7f7adcb8d807ac4da4df1f
http://hdl.handle.net/10261/255695